Thank you to the attendees, faculty, sponsors, and supporters of the Annual Perspectives in Rheumatic Diseases Conference for making the conference a tremendous success! We hope to see you again in 2020. SIGN UP for email updates to keep informed of program developments for our upcoming conference as they become available.
THIS CONFERENCE IS FOR YOU
Rheumatologists • Internists • Family Physicians • Physician Assistants • Nurse Practitioners • Nurses • Pharmacists
After completing this live activity, participants should be better able to:
- Identify the features of a patient who has difficult-to-treat (D2T) rheumatoid arthritis (RA).
- Generate a clinical management plan to address the needs of people with D2T RA.
- Review new and emerging ACR/EULAR guidelines for rheumatic disorders.
- Describe the screening assays for vasculitis and how to interpret the results.
- Match specific cutaneous manifestations with the various connective tissue diseases.
- Distinguish between gout and other crystalline-induced arthropathies and their respective treatments.
- Describe the appropriate use of synovial fluid analysis in the diagnosis of acute arthritis.
- Describe the current and emerging treatment options for giant cell arteritis.
- Recognize evidence-based recommendations for dosing urate-lowering therapies to optimize efficacy in patients with gout.
- Establish treatment plans for gout that achieve targeted levels of serum uric acid.
- Outline the current and emerging therapeutic options that target established and recognized pathways in the pathogenesis of ankylosing spondyloarthropathies.
- Describe the role of the microbiome in eliciting the immune response.
- Identify mechanisms by which the microbiome could cause rheumatic disease.
- Describe how myositis-specific autoantibodies define different types and subtypes of inflammatory myopathy.
- Develop strategies for managing patients with the different types of inflammatory myopathy.
- Describe current therapeutic approaches to symptomatic osteoarthritis.
- Review the diagnostic evaluation for osteopenia and osteoporosis.
- Identify how current and emerging agents might fit in the treatment strategy for osteoporosis.
- Compare and contrast the safety, efficacy, and mechanisms of various agents available for managing pain in the context of autoimmune disorders.
- Determine the optimal manner to incorporate non-pharmacological treatment of pain into clinical practice.
- Demonstrate awareness of current guidelines for management of psoriasis.
- Outline treatment plans for psoriasis that consider the use of current and new agents, and that include strategies for modifying treatment as needed based on results and patient satisfaction.
- Create a treatment plan for psoriatic arthritis that incorporates tools for assessing the impact of psoriatic arthritis and that anticipates the potential need to switch or augment therapy.
- Describe the safety and efficacy of available agents for psoriatic arthritis and develop a treatment strategy for patients with psoriatic arthritis.
- Design effective treatment strategies for the various manifestations of localized and systemic scleroderma including the management of lung disease.
- Develop a strategy for identifying and managing cutaneous adverse reactions.
- Summarize the diagnosis and management of different types of statin-related muscle complaints.
- Summarize current and emerging research on the mechanisms of the pathology of systemic lupus erythematosus and treatment of lupus nephritis.
Accreditation and Designation statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Global Academy for Medical Education, LLC. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.
The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 13.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 13.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
This Live activity, 12th Annual Perspectives in Rheumatic Diseases, with a beginning date of 09/20/2019, has been reviewed and is acceptable for up to 13.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING AND PHARMACY
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 13.5 contact hours (1.35 CEUs) of the Accreditation Council for Pharmacy Education. Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 13.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Nurses will be designated on certificates.